Umbrella Review: Cannabinoids Have Moderate Evidence Only for Chemo Nausea and Ulcerative Colitis QoL
An overview of 68 systematic reviews covering 37 health conditions found no high-certainty evidence for cannabinoids in any condition. Moderate evidence supported benefit only for chemotherapy nausea and quality of life in ulcerative colitis.
Quick Facts
What This Study Found
Evidence certainty was not high for any cannabinoid outcome. Moderate evidence found: CBD may improve quality of life in ulcerative colitis but increases adverse events; cannabinoids appear to have no clinically important benefit for chronic non-cancer pain, MS spasticity pain, or acute postoperative pain; cannabinoids appear to reduce chemotherapy-related nausea and vomiting.
Key Numbers
68 systematic reviews included. 37 health conditions addressed. 8 reviews rated high quality. No high-certainty evidence for any outcome. Moderate evidence for chemotherapy nausea benefit and no benefit for chronic non-cancer pain. For all other outcomes, evidence was low or very low.
How They Did This
Overview of systematic reviews (umbrella review). Identified 68 systematic reviews of randomized trials addressing 37 health conditions. Methodological quality assessed with AMSTAR-2 (8 rated high quality). Evidence certainty graded using GRADE framework.
Why This Research Matters
This is the most comprehensive overview of cannabis therapeutic evidence to date. By synthesizing 68 systematic reviews, it provides a definitive snapshot of where the evidence is strong, moderate, or insufficient, helping clinicians and patients make informed decisions.
The Bigger Picture
Despite thousands of studies, the evidence for most therapeutic cannabis applications remains weak. This overview highlights the gap between public enthusiasm and scientific evidence, and should guide research priorities toward conditions where preliminary signals exist.
What This Study Doesn't Tell Us
Umbrella reviews depend on the quality of underlying systematic reviews. Rapidly evolving cannabis research means some newer studies may not be captured. The GRADE ratings are conservative and may underrate conditions where practical clinical experience suggests benefit.
Questions This Raises
- ?Why does the evidence remain so weak despite decades of cannabis research?
- ?Would standardized cannabis products and better trial designs improve evidence quality?
- ?Which conditions should be prioritized for new rigorous trials?
Trust & Context
- Key Stat:
- 68 systematic reviews, 37 conditions: no high-certainty evidence for any
- Evidence Grade:
- Strong: comprehensive umbrella review with AMSTAR-2 quality assessment and GRADE evidence ratings.
- Study Age:
- Published in 2022.
- Original Title:
- Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews.
- Published In:
- Phytotherapy research : PTR, 36(1), 5-21 (2022)
- Authors:
- Riera, Rachel(2), Pacheco, Rafael Leite(2), Bagattini, Ângela Maria, Martimbianco, Ana Luiza Cabrera
- Database ID:
- RTHC-04169
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
What conditions does cannabis actually help with?
Based on the highest available evidence, cannabinoids appear beneficial for reducing chemotherapy-related nausea and vomiting (moderate evidence). For chronic pain, multiple sclerosis spasticity, and most other conditions, the evidence is either insufficient or shows no clinically meaningful benefit.
Why is the evidence so weak for something millions of people use?
Cannabis research faces unique challenges: legal restrictions limit clinical trials, product inconsistency makes comparisons difficult, and many studies are small or poorly designed. The gap between patient experience and trial evidence remains wide.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04169APA
Riera, Rachel; Pacheco, Rafael Leite; Bagattini, Ângela Maria; Martimbianco, Ana Luiza Cabrera. (2022). Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews.. Phytotherapy research : PTR, 36(1), 5-21. https://doi.org/10.1002/ptr.7263
MLA
Riera, Rachel, et al. "Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews.." Phytotherapy research : PTR, 2022. https://doi.org/10.1002/ptr.7263
RethinkTHC
RethinkTHC Research Database. "Efficacy and safety of therapeutic use of cannabis derivativ..." RTHC-04169. Retrieved from https://rethinkthc.com/research/riera-2022-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.